Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 10/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14025681 | 0.94 | HDAC1 (0.52) | HDAC1HDAC6AKR1C3MEN1KMT2A | |
| SCHEMBL14025707 | 0.93 | HDAC1 (0.48) | HDAC1HDAC6AKR1C3MEN1KMT2A | |
| SCHEMBL14025483 | 0.90 | HDAC1 (0.56) | HDAC1HDAC6AKR1C3MEN1KMT2A | |
| SCHEMBL14025706 | 0.87 | HDAC1 (0.50) | HDAC1HDAC6MEN1KMT2APOLB | |
| SCHEMBL14025497 | 0.84 | HDAC1 (0.59) | HDAC1HDAC6CXCR4NAMPT | |
| SCHEMBL14025534 | 0.83 | HDAC1 (0.56) | HDAC1HDAC6MEN1KMT2ACXCR4 | |
| SCHEMBL14068046 | 0.81 | CXCR4 (0.50) | AKR1C3CXCR4 | |
| SCHEMBL14025635 | 0.81 | HDAC6 (0.55) | HDAC1HDAC6KMT2ACXCR4 | |
| SCHEMBL4058966 | 0.78 | HDAC1 (0.50) | HDAC1HDAC6POLBCXCR4 | |
| SCHEMBL14025631 | 0.78 | HDAC1 (0.49) | HDAC1HDAC6MEN1KMT2ACXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008109154-A1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | HDAC1 703/4885HDAC6 1192/4885AKR1C3 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.